NCT05293548

A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)

A Randomized, Controlled Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) in Population Aged 18 Years and Above

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 516 (actual)
• Sponsor: National Vaccine and Serum Institute, China · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

A total of 516 healthy subjects aged 18 years and above who have been vaccinated with 2 doses/3 doses of inactivated COVID-19 vaccine, will be enrolled, and randomly assigned to experimental group and control group in a 1:1 ratio, with 258 subjects in each sequential group.

Conditions

• COVID-19

Interventions

Type	Name	Description
BIOLOGICAL	Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)	Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09) in the deltoid muscle of the upper arm
BIOLOGICAL	Inactivated COVID-19 vaccine (Vero cells)	Biological/Vaccine: Inactivated COVID-19 vaccine (Vero cells) Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm

Timeline

• Start date: 2022-05-25
• Primary completion: 2023-05-01
• Completion: 2023-08-01
• First posted: 2022-03-24
• Last updated: 2023-02-02

Locations

1 site across 1 country: United Arab Emirates